Cancer Policy Makary: Level of evidence is an artificial and dogmatic construct June 06, 2025Vol.51 No.22By Jacquelyn Cobb
Clinical Roundup RWE and phase I data support the role of Orserdu for ER+, HER2- advanced or metastatic breast cancer December 06, 2024Vol.50 No.45
In Brief COTA, Panalgo collaborate to enhance AI & RWD-enabled cancer care September 13, 2024Vol.50 No.34
RWE study pinpoints gaps in mental health care utilization among parents of children with cancer May 17, 2024Vol.50 No.20By McKenzie Prillaman
Drugs & Targets COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI April 19, 2024Vol.50 No.16
Clinical Roundup Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows April 12, 2024Vol.50 No.15
In Brief Michael Egger, Christopher Manz, Serena Phillips receive 2023 Real-World Data Impact Award from ACS, Flatiron March 08, 2024Vol.50 No.10
Conversation with The Cancer Letter Ellen Sigal, Roy Herbst: Friends and FDA to focus on real-world evidence, AI, and streamlined trials in 2024 February 09, 2024Vol.50 No.06By Paul Goldberg and Matthew Bin Han Ong
Clinical Roundup JNCCN study: Real world data shows impact of immunotherapy in populations underrepresented in clinical trials December 15, 2023Vol.49 No.46
Guest Editorial Patients are the key to disruptive innovation in cancer. Why aren’t they at the table? November 10, 2023Vol.49 No.42By Jenny Ahlstrom
